Kevin Y. Xu, MD MPH

Division of Addiction Science, Prevention, and Treatment, Department of Psychiatry, Washington University School of Medicine, St. Louis, Missouri; Washington University School of Public Health, St. Louis, Missouri

  • 4Articles
  • 23.1KReads1
  • 2021–2026Active
  • 17Collaborators
  • 22Citations2

1 Read counts for articles published before 2020 may include some non-human traffic.

2 Citation counts provided by Crossref.

About

Kevin Y. Xu, MD MPH, is affiliated with the Division of Addiction Science, Prevention, and Treatment in the Department of Psychiatry and the School of Public Health at Washington University School of Medicine, St. Louis. Xu has published on topics including addiction, COVID-19, patient care, psychedelics, and psychotic disorders. His work addresses hallucinogen-psychosis associations, telepsychiatry during the COVID-19 public health emergency, treatments related to opioid use disorder, and kratom use with co-occurring substance use disorders. Xu has collaborated frequently with Carrie M. Mintz, Laura J. Bierut, Richard A. Grucza, Anne L. Glowinski, and Arpana Agrawal.

Publications

JCP
Hallucinogen–Psychosis Associations Are Confounded by Baseline Psychiatric History
Original Research ▶ Video

Hallucinogen–Psychosis Associations Are Confounded by Baseline Psychiatric History

June 10, 2026

Apparent associations between hallucinogen use and psychosis appear largely attributable to baseline psychiatric comorbidities rather than direct causal effects.
, , , et al
PCC
Structural Racism and Telepsychiatry During the COVID-19 Pandemic
Review Article

Structural Racism and Telepsychiatry During the COVID-19 Pandemic

November 2, 2023

Data on whether psychiatry can be practiced effectively via telephone are lacking. This study examined the racial and sociodemographic distribution of people receiving audiovisual versus audio-only telepsychiatry since the...
, ,
JCP
Association of Bupropion and Opioid Use Disorder Medications With Stimulant-Related Admissions
Original Research

Association of Bupropion and Opioid Use Disorder Medications With Stimulant-Related Admissions

June 20, 2022

This study investigated whether bupropion and OUD medications (buprenorphine, naltrexone, and methadone) are associated with decreased stimulant-related ED admissions and hospitalizations in people with OUD who had at least...
, , , et al
PCC
Brief Report

Prevalence of Kratom Use and Co-Occurring Substance Use Disorders

August 5, 2021

Kratom is a novel psychoactive drug often used to self-manage pain and opioid withdrawal. This report describes the prevalence of kratom use and co-occurring substance use disorders using the...
, , , et al

Physicians Postgraduate Press, Inc. (PPP) makes no warranties about the accuracy or completeness of any information published in The Journal of Clinical Psychiatry or other PPP materials, and disclaims liability for any use or non-use of that information. Clinicians should not rely solely on these materials and should exercise their own professional judgment when making patient care decisions on an individualized basis.

Learn More About Ketamine and Psychedelics

Listen to the Podcast
The Journal of Clinical Psychiatry podcast cover with Benjamin Brody, MD

Subscribe to read
more articles

Subscribe